Skip to content

Study · Observational study · n = 30 · 1995

3 results

Plasma growth hormone response to growth hormone-releasing hexapeptide (GH-RP-6) in children with short stature.

Pombo M, Barreiro J, Peñalva A, Mallo F, Mallo F, Casanueva FF, Dieguez C

Acta paediatrica (Oslo, Norway : 1992)1 Aug 1995Cited by 13 (Europe PMC)

PMID7488815 (opens in a new tab)DOI10.1111/j.1651-2227.1995.tb13790.x (opens in a new tab)PepBankPUB-07488815
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanObservational studyEfficacy outcome

    In children with short stature and normal children, GH responses to GHRP‑6 overlapped considerably between the three groups on an individual basis.

    In plain wordsIn children, growth hormone responses to GHRP‑6 overlapped widely between children with and without deficiency, so one test result could not tell them apart.

    Peptide
    GHRP-6
    Outcome
    Not applicableIndividual overlap of GH responses to GHRP-6 between groups
    Study

    n = 30

    Comparator
    Normal children
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    Dose not stated · intravenousAs given in this study (human).

    Source sentences

    Summary
    However, on an individual basis, a considerable degree of overlapping in responses among the three groups was evident.
    2 context sentences
    Summary · context
    Eighteen children with short stature were evaluated for growth hormone (GH) reserve after pharmacological tests and a single iv injection of GH-RP-6.
    Summary · context
    The results were compared with a group of 12 normal children.
  2. 02HumanObservational studyEfficacy outcome

    In children with idiopathic GH deficiency, the GH response to a single iv injection of GHRP‑6 was lower than in normal children.

    In plain wordsIn children with growth hormone deficiency, GHRP‑6 raised growth hormone less than in normal children.

    Peptide
    GHRP-6
    Outcome
    DecreaseGH response to GHRP-6 in idiopathic GH deficiency (group A)
    Study

    n = 22

    Comparator
    Normal children
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    Dose not stated · intravenousAs given in this study (human).

    Source sentences

    Summary
    As a group, patients in group A showed a lower GH response to GH-RP-6
    2 context sentences
    Summary · context
    Eighteen children with short stature were evaluated for growth hormone (GH) reserve after pharmacological tests and a single iv injection of GH-RP-6.
    Summary · context
    The results were compared with a group of 12 normal children.
  3. 03HumanObservational studyEfficacy outcome

    In short children with normal GH secretion on stimulation tests but reduced endogenous GH secretion, the GH response to GHRP‑6 was similar to normal controls.

    In plain wordsIn short children with normal stimulation tests, GHRP‑6 raised growth hormone about as much as in normal children.

    Peptide
    GHRP-6
    Outcome
    No significant changeGH response to GHRP-6 in short children with normal GH secretion (group B)
    Study

    n = 20

    Comparator
    Normal children
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    Dose not stated · intravenousAs given in this study (human).

    Source sentences

    Summary
    while patients in group B had a similar response as normal controls.
    2 context sentences
    Summary · context
    Eighteen children with short stature were evaluated for growth hormone (GH) reserve after pharmacological tests and a single iv injection of GH-RP-6.
    Summary · context
    The results were compared with a group of 12 normal children.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:58 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:13 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.